IgE Sensitization to the Nonspecific Lipid-Transfer Protein Ara h 9 and Peanut-Associated Bronchospasm
Table 3
Clinical and IgE parameters of 192 patients with peanut allergy, with or without symptoms of bronchospasm.
No symptoms
Wheeze
Wheeze and dyspnea
Clinical characteristics
Number
98
46
48
% adults
6%
15%
3.0 (0.8–11.1)
23%
3.8 (1.2–12.6)*
% male gender
53%
61%
0.5 (0.2–1.1)
52%
0.7 (0.8–1.6)
AD
75%
70%
0.8 (0.3–2.0)
69%
0.7 (0.3–1.7)
Asthma
49%
71%
3.3 (1.3–8.0)*
65%
2.3 (1.0–5.1)*
Rhinitis
28%
39%
1.4 (0.6–3.4)
54%
3.6 (1.5–8.7)**
Peanut allergen specific IgE
peanut sIgE
83%
78%
0.3 (0.1–1.2)
81%
1.1 (0.3–4.0)
Ara h 1 sIgE
37%
41%
1.1 (0.4–3.4)
41%
1.5 (0.5–4.8)
Ara h 2 sIgE
63%
64%
1.7 (0.5–6.5)
57%
0.4 (0.1–1.4)
Ara h 3 sIgE
24%
27%
0.8 (0.2–2.5)
38%
2.3 (0.8–7.1)
Ara h 8 sIgE
15%
20%
0.8 (0.3–2.5)
25%
0.9 (0.3–2.6)
Ara h 9 sIgE
9%
25%
6.1 (1.9–9.9)**
28%
3.2 (1.1–10.6)*
Timothy grass pollen allergen specific IgE
Phl p 1
54%
64%
2.3 (0.7–7.4)
39%
0.3 (0.1–1.2)
Phl p 4
64%
69%
1.0 (0.3–3.6)
64%
1.4 (0.4–4.6)
Phl p 5B
45%
44%
0.5 (0.2–5.4)
42%
2.4 (0.4–4.9)
Phl p 12
12%
16%
1.2 (0.3–5.4)
18%
1.1 (0.2–4.9)
Data are given as percentage of group. Specific IgE ≥ 0.35 kAU/L is defined as “sensitized.” Statistical analysis was performed using multinomial logistic regression analysis quoting Relative Risk (95% confidence interval). * value < 0.05, ** value < 0.005.
